An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer
New Jersey’s research-based biopharmaceutical industry is constantly developing new cures and treatments that benefit New Jerseyans and patients worldwide. Over the past two years, we all have witnessed firsthand the industry’s remarkable and rapid response to identifying, treating and inoculating against COVID-19 with innovative diagnostics, antivirals and vaccines. At the same time, industry critics assert that biopharmaceutical companies are the root cause of whatever ails our country’s health care system. This conclusion is simply not based in fact, it creates a fundamentally inaccurate perception of the industry and it does a disservice to one of the pillars of New Jersey’s economy and the more than 400,000 New Jerseyans who are connected to our life sciences industry. Read more here